![]() Music |
![]() Video |
![]() Movies |
![]() Chart |
![]() Show |
![]() |
Bevacizumab’s Value in Recurrent Ovarian Cancer (Targeted Oncology) View |
![]() |
When to Add Bevacizumab for Recurrent Ovarian Cancer (OncLive) View |
![]() |
Bevacizumab for Recurrent Ovarian Cancer (OncLive) View |
![]() |
Bevacizumab in Ovarian Cancer (OncLive) View |
![]() |
Bevacizumab in Platinum-Resistant Ovarian Cancer (OncLive) View |
![]() |
Ovarian Cancer: Maintenance Following Frontline Bevacizumab (OncLive) View |
![]() |
Recurrent Ovarian Cancer: Third-Line Therapy and Beyond (Targeted Oncology) View |
![]() |
Maintenance Therapy: PARP Inhibitor or Bevacizumab (OncLive) View |
![]() |
Adjuvant Chemotherapy + Bevacizumab for Ovarian Cancer (Targeted Oncology) View |
![]() |
Expert report on survival data from pivotal trials with PARP inhibitors for BRCA-mut. Ovarian Cancer (European Society for Medical Oncology (ESMO)) View |